Home » Stocks » AZRX

AzurRx BioPharma, Inc. (AZRX)

Stock Price: $1.30 USD -0.09 (-6.47%)
Updated Mar 3, 2021 4:00 PM EST - Market closed
Market Cap 76.39M
Revenue (ttm) n/a
Net Income (ttm) -16.55M
Shares Out 28.52M
EPS (ttm) -0.90
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 3
Last Price $1.30
Previous Close $1.39
Change ($) -0.09
Change (%) -6.47%
Day's Open 1.40
Day's Range 1.29 - 1.45
Day's Volume 2,286,588
52-Week Range 0.37 - 2.63

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 days ago

DELRAY BEACH, Fla., March 02, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, re...

GlobeNewsWire - 1 week ago

Former Chairman Edward J. Borkowski to continue as the lead independent director on the board Former Chairman Edward J. Borkowski to continue as the lead independent director on the board

GlobeNewsWire - 2 weeks ago

DELRAY BEACH, Fla., Feb. 16, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, rec...

Benzinga - 3 weeks ago

Usana Health Sciences (NYSE: USNA) shares are trading higher after the company reported better-than-expected Q4 EPS and sales results and issued fiscal year 2021 EPS and sales guidance above e...

Other stocks mentioned: USNA, ABCL, CGIX
GlobeNewsWire - 3 weeks ago

Phase 2 Study of oral niclosamide planned for 1H 2021

GlobeNewsWire - 3 weeks ago

DELRAY BEACH, Fla., Feb. 08, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, rec...

Seeking Alpha - 1 month ago

$8 Million Offering to Fuel Acquisitions and Clinical Studies Leading Therapeutic for COVID-19 Related Gastrointestinal Infections. MS1819 a Better Mousetrap vs Porcine Competitors.

GlobeNewsWire - 1 month ago

DELRAY BEACH, Fla., Jan. 28, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, rec...

Benzinga - 1 month ago

AzurRx BioPharma (NASDAQ: AZRX) shares are trading higher Friday amid a surge in session volume for the day. On Thursday, the company announced it has started dosing in the mid-stage cystic fi...

Zacks Investment Research - 1 month ago

AzurRX (AZRX) is developing its pipeline candidate, MS1819, as monotherapy as well in combination with standard of care for treating exocrine pancreatic insufficiency in patients with cystic f...

GlobeNewsWire - 1 month ago

DELRAY BEACH, Fla., Jan. 12, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the develop...

GlobeNewsWire - 1 month ago

DELRAY BEACH, Fla., Jan. 08, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, rec...

GlobeNewsWire - 1 month ago

DELRAY BEACH, Fla., Jan. 06, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a company specializing in the development of targeted, non-systemic th...

GlobeNewsWire - 2 months ago

DELRAY BEACH, Fla., Jan. 04, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a company specializing in the development of non-systemic therapies fo...

GlobeNewsWire - 3 months ago

DELRAY BEACH, Fla., Nov. 30, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant t...

GlobeNewsWire - 3 months ago

Potential to add additional study arm utilizing immediate release capsules

GlobeNewsWire - 3 months ago

DELRAY BEACH, Fla., Nov. 10, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant t...

GlobeNewsWire - 4 months ago

NEW YORK, Oct. 29, 2020 (GLOBE NEWSWIRE) -- via InvestorWire -- AzurRx BioPharma, Inc. ( NASDAQ: AZRX ) (“AzurRx” or the “Company”), a New York-based biopharmaceutical company specializing in ...

GlobeNewsWire - 4 months ago

NEW YORK, Oct. 21, 2020 (GLOBE NEWSWIRE) --  AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies ...

GlobeNewsWire - 4 months ago

NEW YORK, Oct. 14, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies f...

GlobeNewsWire - 5 months ago

Abstracts to Focus on:

GlobeNewsWire - 6 months ago

NEW YORK, Aug. 31, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies...

GlobeNewsWire - 6 months ago

NEW YORK, Aug. 17, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies...

GlobeNewsWire - 6 months ago

NEW YORK, Aug. 13, 2020 (GLOBE NEWSWIRE) --  AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapie...

GlobeNewsWire - 6 months ago

NEW YORK, Aug. 12, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapie...

GlobeNewsWire - 6 months ago

Management to discuss the interim results on call scheduled for today, August 11, 2020, at 4:30 p.m. Eastern Time

PRNewsWire - 7 months ago

NEW YORK, July 22, 2020 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiducia...

GlobeNewsWire - 7 months ago

NEW YORK, July 22, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies...

GlobeNewsWire - 7 months ago

NEW YORK, July 20, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma (NASDAQ: AZRX ), (“AzurRx” or the “Company”), today announced that on July 16, 2020, it entered into a Convertible Preferred Sto...

GlobeNewsWire - 9 months ago

NEW YORK, May 07, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX ) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapie...

GlobeNewsWire - 10 months ago

NEW YORK, April 21, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapi...

GlobeNewsWire - 10 months ago

NEW YORK, April 16, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX ) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant  thera...

GlobeNewsWire - 10 months ago

Seasoned veteran with decades of strategic and global leadership experience Seasoned veteran with decades of strategic and global leadership experience

GlobeNewsWire - 11 months ago

NEW YORK, April 01, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapie...

GlobeNewsWire - 1 year ago

NEW YORK, Feb. 18, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies...

GlobeNewsWire - 1 year ago

NEW YORK, Jan. 13, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies...

GlobeNewsWire - 1 year ago

NEW YORK, Jan. 09, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (AzurRx or the Company), a company specializing in the development of non-systemic, recombinant therapies for...

GlobeNewsWire - 1 year ago

NEW YORK, Jan. 03, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapie...

GlobeNewsWire - 1 year ago

NEW YORK, Nov. 14, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies...

GlobeNewsWire - 1 year ago

NEW YORK, Oct. 22, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapie...

GlobeNewsWire - 1 year ago

NEW YORK, Oct. 17, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies...

GlobeNewsWire - 1 year ago

NEW YORK, Oct. 15, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies...

GlobeNewsWire - 1 year ago

Founder and Former CEO Thijs Spoor to Remain on Board of Directors Founder and Former CEO Thijs Spoor to Remain on Board of Directors

Benzinga - 1 year ago

Shares of thinly-traded nano-cap biotech AzurRx BioPharma Inc (NASDAQ: AZRX) are trading sharply lower following a clinical readout from the company.

GlobeNewsWire - 1 year ago

Excellent safety results seen in CF patients, with CFA in line with previous studies and no need for a protease

About AZRX

AzurRx BioPharma, a clinical stage biopharmaceutical company, focuses on the development of recombinant proteins for the treatment of gastrointestinal diseases. Its therapeutic products administer patients as oral non-systemic biologics. The company's lead therapeutic is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (for cystic fibrosis and chronic pancreatitis patients). It is also developing two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor, includin... [Read more...]

Industry
Biotechnology
IPO Date
Oct 11, 2016
CEO
James R. Sapirstein R.Ph., M.B.A.
Employees
10
Stock Exchange
NASDAQ
Ticker Symbol
AZRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for AZRX stock is "Buy." The 12-month stock price forecast is 4.50, which is an increase of 246.15% from the latest price.

Price Target
$4.50
(246.15% upside)
Analyst Consensus: Buy